» Articles » PMID: 34758478

Pre-existing Polymerase-specific T Cells Expand in Abortive Seronegative SARS-CoV-2

Abstract

Individuals with potential exposure to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) do not necessarily develop PCR or antibody positivity, suggesting that some individuals may clear subclinical infection before seroconversion. T cells can contribute to the rapid clearance of SARS-CoV-2 and other coronavirus infections. Here we hypothesize that pre-existing memory T cell responses, with cross-protective potential against SARS-CoV-2 (refs. ), would expand in vivo to support rapid viral control, aborting infection. We measured SARS-CoV-2-reactive T cells, including those against the early transcribed replication-transcription complex (RTC), in intensively monitored healthcare workers (HCWs) who tested repeatedly negative according to PCR, antibody binding and neutralization assays (seronegative HCWs (SN-HCWs)). SN-HCWs had stronger, more multispecific memory T cells compared with a cohort of unexposed individuals from before the pandemic (prepandemic cohort), and these cells were more frequently directed against the RTC than the structural-protein-dominated responses observed after detectable infection (matched concurrent cohort). SN-HCWs with the strongest RTC-specific T cells had an increase in IFI27, a robust early innate signature of SARS-CoV-2 (ref. ), suggesting abortive infection. RNA polymerase within RTC was the largest region of high sequence conservation across human seasonal coronaviruses (HCoV) and SARS-CoV-2 clades. RNA polymerase was preferentially targeted (among the regions tested) by T cells from prepandemic cohorts and SN-HCWs. RTC-epitope-specific T cells that cross-recognized HCoV variants were identified in SN-HCWs. Enriched pre-existing RNA-polymerase-specific T cells expanded in vivo to preferentially accumulate in the memory response after putative abortive compared to overt SARS-CoV-2 infection. Our data highlight RTC-specific T cells as targets for vaccines against endemic and emerging Coronaviridae.

Citing Articles

Coronavirus replicase epitopes induce cross-reactive CD8 T cell responses in SARS-CoV-2-naive people with HIV-1.

Schmidt K, Geissler P, Schuster E, Schulein C, Harrer E, Schonau V iScience. 2025; 28(3):111949.

PMID: 40034846 PMC: 11872457. DOI: 10.1016/j.isci.2025.111949.


Immunologic and inflammatory consequences of SARS-CoV-2 infection and its implications in renal disease.

Naiditch H, Betts M, Larman H, Levi M, Rosenberg A Front Immunol. 2025; 15:1376654.

PMID: 40012912 PMC: 11861071. DOI: 10.3389/fimmu.2024.1376654.


Pre-pandemic cross-reactive antibody and cellular responses against SARS-CoV-2 among female sex workers in Dakar, Senegal.

Herrera B, Chaplin B, Mboup S, Abdullahi A, He M, Fisher S Front Public Health. 2025; 13:1522733.

PMID: 39916712 PMC: 11798920. DOI: 10.3389/fpubh.2025.1522733.


T cell-mediated protection in absence of virus neutralizing antibodies.

Alpizar Y, Dallmeier K Nat Microbiol. 2025; 10(2):277-278.

PMID: 39849084 DOI: 10.1038/s41564-024-01921-5.


homeRNA self-blood collection enables high-frequency temporal profiling of presymptomatic host immune kinetics to respiratory viral infection: a prospective cohort study.

Lim F, Lea H, Dostie A, Kim S, van Neel T, Hassan G EBioMedicine. 2025; 112:105531.

PMID: 39826256 PMC: 11786902. DOI: 10.1016/j.ebiom.2024.105531.


References
1.
Tan A, Linster M, Tan C, Bert N, Chia W, Kunasegaran K . Early induction of functional SARS-CoV-2-specific T cells associates with rapid viral clearance and mild disease in COVID-19 patients. Cell Rep. 2021; 34(6):108728. PMC: 7826084. DOI: 10.1016/j.celrep.2021.108728. View

2.
Oberhardt V, Luxenburger H, Kemming J, Schulien I, Ciminski K, Giese S . Rapid and stable mobilization of CD8 T cells by SARS-CoV-2 mRNA vaccine. Nature. 2021; 597(7875):268-273. PMC: 8426185. DOI: 10.1038/s41586-021-03841-4. View

3.
Zhao J, Zhao J, Mangalam A, Channappanavar R, Fett C, Meyerholz D . Airway Memory CD4(+) T Cells Mediate Protective Immunity against Emerging Respiratory Coronaviruses. Immunity. 2016; 44(6):1379-91. PMC: 4917442. DOI: 10.1016/j.immuni.2016.05.006. View

4.
Sekine T, Perez-Potti A, Rivera-Ballesteros O, Stralin K, Gorin J, Olsson A . Robust T Cell Immunity in Convalescent Individuals with Asymptomatic or Mild COVID-19. Cell. 2020; 183(1):158-168.e14. PMC: 7427556. DOI: 10.1016/j.cell.2020.08.017. View

5.
Mateus J, Grifoni A, Tarke A, Sidney J, Ramirez S, Dan J . Selective and cross-reactive SARS-CoV-2 T cell epitopes in unexposed humans. Science. 2020; 370(6512):89-94. PMC: 7574914. DOI: 10.1126/science.abd3871. View